$LGVN
Longeveron Inc. Stock $lgvn

$lgvn Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-Q Financial Statement

#000121390023039003 Filed on May 12, 2023

Income Statement

Concept	2023 Q1	2022 Q1
Revenue	$279.0K	$370.0K
YoY Change	-24.59%	-2.63%
Cost Of Revenue	$203.0K	$70.00K
YoY Change	190.0%	-69.57%
Gross Profit	$76.00K	$300.0K
YoY Change	-74.67%	100.0%
Gross Profit Margin	27.24%	81.08%
Selling, General & Admin	$2.012M	$2.267M
YoY Change	-11.25%	0.31%
% of Gross Profit	2647.37%	755.67%
Research & Development	$2.780M	$1.427M
YoY Change	94.81%	5.7%
% of Gross Profit	3657.89%	475.67%
Depreciation & Amortization	$200.0K	$188.0K
YoY Change	6.38%	-6.0%
% of Gross Profit	263.16%	62.67%
Operating Expenses	$4.792M	$3.694M
YoY Change	29.72%	2.61%
Operating Profit	-$4.716M	-$3.394M
YoY Change	38.95%	-1.62%
Interest Expense		-$100.0K
YoY Change
% of Operating Profit
Other Income/Expense, Net	$69.00K	-$16.00K
YoY Change	-531.25%	-132.0%
Pretax Income	-$4.647M	-$3.510M
YoY Change	32.39%	12.86%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$4.647M	-$3.510M
YoY Change	32.39%	12.86%
Net Earnings / Revenue	-1665.59%	-948.65%
Basic Earnings Per Share	-$0.22	-$0.17
Diluted Earnings Per Share	-$0.22	-$167.9K
COMMON SHARES
Basic Shares Outstanding	21.03M shares	20.91M shares
Diluted Shares Outstanding	21.03M shares	20.91M shares

Balance Sheet

Concept	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$13.68M	$30.58M
YoY Change	-55.28%	25.02%
Cash & Equivalents	$4.984M	$22.13M
Short-Term Investments	$8.693M	$8.449M
Other Short-Term Assets	$1.097M	$1.190M
YoY Change	-7.82%	41.67%
Inventory
Prepaid Expenses
Receivables	$96.00K	$96.00K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$14.87M	$31.87M
YoY Change	-53.34%	25.96%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.810M	$4.711M
YoY Change	-40.35%	-13.24%
Goodwill
YoY Change
Intangibles	$2.425M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$247.0K	$234.0K
YoY Change	5.56%	30.0%
Total Long-Term Assets	$6.938M	$7.306M
YoY Change	-5.04%	2.47%
TOTAL ASSETS
Total Short-Term Assets	$14.87M	$31.87M
Total Long-Term Assets	$6.938M	$7.306M
Total Assets	$21.81M	$39.17M
YoY Change	-44.33%	20.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$457.0K	$561.0K
YoY Change	-18.54%	-37.67%
Accrued Expenses	$613.0K	$1.334M
YoY Change	-54.05%	-9.86%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change		-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.595M	$2.400M
YoY Change	49.79%	-13.67%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change		-100.0%
Other Long-Term Liabilities	$1.895M	$2.467M
YoY Change	-23.19%	-18.04%
Total Long-Term Liabilities	$1.895M	$2.467M
YoY Change	-23.19%	-21.93%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.595M	$2.400M
Total Long-Term Liabilities	$1.895M	$2.467M
Total Liabilities	$5.490M	$4.867M
YoY Change	12.8%	-18.06%
SHAREHOLDERS EQUITY
Retained Earnings	-$67.42M
YoY Change
Common Stock	$6.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$100.0K
YoY Change
Treasury Stock Shares
Shareholders Equity	$16.32M	$34.31M
YoY Change
Total Liabilities & Shareholders Equity	$21.81M	$39.17M
YoY Change	-44.33%	20.79%

Cashflow Statement

Concept	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$4.647M	-$3.510M
YoY Change	32.39%	12.86%
Depreciation, Depletion And Amortization	$200.0K	$188.0K
YoY Change	6.38%	-6.0%
Cash From Operating Activities	-$5.848M	-$4.152M
YoY Change	40.85%	37.03%
INVESTING ACTIVITIES
Capital Expenditures	$42.00K	-$118.0K
YoY Change	-135.59%
Acquisitions
YoY Change
Other Investing Activities	$461.0K	$885.0K
YoY Change	-47.91%
Cash From Investing Activities	$346.0K	$767.0K
YoY Change	-54.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$17.00K	-141.0K
YoY Change	-87.94%	-100.53%
NET CHANGE
Cash From Operating Activities	-$5.848M	-4.152M
Cash From Investing Activities	$346.0K	767.0K
Cash From Financing Activities	-$17.00K	-141.0K
Net Change In Cash	-$5.519M	-3.526M
YoY Change	56.52%	-114.91%
FREE CASH FLOW
Cash From Operating Activities	-$5.848M	-$4.152M
Capital Expenditures	$42.00K	-$118.0K
Free Cash Flow	-$5.890M	-$4.034M
YoY Change	46.01%	33.14%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-40060
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-2174146
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	1951 NW 7th Avenue
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 520
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Miami
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33136
CY2023Q1	dei	City Area Code CityAreaCode	(305)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	909-0840
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2023Q1	dei	Trading Symbol TradingSymbol	LGVN
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4984000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10503000	usd
CY2023Q1	us-gaap	Other Short Term Investments OtherShortTermInvestments	8693000	usd
CY2022Q4	us-gaap	Other Short Term Investments OtherShortTermInvestments	9155000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1097000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	404000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	96000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	218000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	14870000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	20280000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2810000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2949000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2425000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2409000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1456000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1531000	usd
CY2023Q1	us-gaap	Other Assets OtherAssets	247000	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	244000	usd
CY2023Q1	us-gaap	Assets Assets	21808000	usd
CY2022Q4	us-gaap	Assets Assets	27413000	usd
CY2023Q1	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	457000	usd
CY2022Q4	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	1751000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	613000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	650000	usd
CY2023Q1	us-gaap	Loans Payable Current LoansPayableCurrent	571000	usd
CY2022Q4	us-gaap	Loans Payable Current LoansPayableCurrent	564000	usd
CY2023Q1	lgvn	Estimated Lawsuit Liability EstimatedLawsuitLiability	1398000	usd
CY2022Q4	lgvn	Estimated Lawsuit Liability EstimatedLawsuitLiability	1398000	usd
CY2023Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	556000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	506000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	3595000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4869000	usd
CY2023Q1	lgvn	Lease Liability LeaseLiability	1895000	usd
CY2022Q4	lgvn	Lease Liability LeaseLiability	2041000	usd
CY2023Q1	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	1895000	usd
CY2022Q4	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	2041000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	5490000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	6910000	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	6000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	6000	usd
CY2023Q1	lgvn	Common Stock Value One CommonStockValueOne	15000	usd
CY2022Q4	lgvn	Common Stock Value One CommonStockValueOne	15000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	84116000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	83712000	usd
CY2023Q1	us-gaap	Treasury Stock Value TreasuryStockValue	100000	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	100000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-67420000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-62773000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-299000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-357000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	16318000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	20503000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	21808000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27413000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	238000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	310000	usd
CY2023Q1	lgvn	Grant Revenue GrantRevenue	41000	usd
CY2022Q1	lgvn	Grant Revenue GrantRevenue	60000	usd
CY2023Q1	us-gaap	Revenues Revenues	279000	usd
CY2022Q1	us-gaap	Revenues Revenues	370000	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	203000	usd
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	205000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	76000	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	165000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1855000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1980000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2780000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1292000	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	157000	usd
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	287000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	4792000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	3559000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4716000	usd
CY2022Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-306000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-38000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3394000	usd
CY2023Q1	us-gaap	Other Income OtherIncome	69000	usd
CY2022Q1	us-gaap	Other Income OtherIncome	-116000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	69000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-116000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-4647000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-3510000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.22
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21033610	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20911203	shares
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-4647000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3510000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Before Reclassification Adjustments Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax	-58000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4589000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3510000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	20503000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	-17000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	421000	usd
CY2023Q1	lgvn	Stock Issued During Period Unrealized Loss Attributable To Change In Market Value Of Available For Sale Investments StockIssuedDuringPeriodUnrealizedLossAttributableToChangeInMarketValueOfAvailableForSaleInvestments	58000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-4647000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	16318000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	37453000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	-128000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	491000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3510000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	34306000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-4647000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3510000	usd
CY2023Q1	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	238000	usd
CY2022Q1	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	188000	usd
CY2023Q1	lgvn	Change In Fair Value Of Marketable Securities ChangeInFairValueOfMarketableSecurities	72000	usd
CY2022Q1	lgvn	Change In Fair Value Of Marketable Securities ChangeInFairValueOfMarketableSecurities	54000	usd
CY2023Q1	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	421000	usd
CY2022Q1	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	491000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-122000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	41000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	694000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	908000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	2000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	57000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1294000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-7000	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-50000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-604000	usd
CY2023Q1	lgvn	Increase Decrease Lease Liability IncreaseDecreaseLeaseLiability	76000	usd
CY2022Q1	lgvn	Increase Decrease Lease Liability IncreaseDecreaseLeaseLiability	64000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5848000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4152000	usd
CY2022Q4	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	64815000	usd
CY2022	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	9826717000	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	461000	usd
CY2022Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	885000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	42000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	47000	usd
CY2023Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	73000	usd
CY2022Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	71000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	346000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	767000	usd
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	17000	usd
CY2022Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	141000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-17000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-141000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-5519000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-3526000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10503000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25658000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4984000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22132000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	68000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	379000	usd
CY2023Q1	lgvn	Recurring Loss RecurringLoss	4600000	usd
CY2022Q1	lgvn	Recurring Loss RecurringLoss	3500000	usd
CY2023Q1	lgvn	Accmulated Deficit AccmulatedDeficit	67400000	usd
CY2023Q1	us-gaap	Cash Cash	5000000	usd
CY2023Q1	lgvn	Short Term Investments Amount ShortTermInvestmentsAmount	8700000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of estimates:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The presentation of condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q1	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	66862000	usd
CY2022Q4	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	64815000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	168000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	224000	usd
CY2023Q1	lgvn	Shortterm Investments ShorttermInvestments	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Marketable securities:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Marketable securities at March 31, 2023 and December 31, 2022 consisted of marketable fixed income securities, primarily corporate bonds, as well as U.S. Government and agency obligations which are categorized as available for sale securities and are thus marked to market and stated at fair value in accordance with ASC 820 <i>Fair</i> <i>Value Measurement</i>. These investments are considered Level 1 and Level 2 investments within the ASC 820 fair value hierarchy. The fair value of Level 1 investments, including cash equivalents, money funds and U.S. government securities, are substantially based on quoted market prices. The fair value of corporate bonds is determined using standard market valuation methodologies, including discounted cash flows, matrix pricing and/or other similar techniques. The inputs to these valuation techniques include but are not limited to market interest rates, credit rating of the issuer or counterparty, industry sector of the issuer, coupon rate, call provisions, maturity, estimated duration and assumptions regarding liquidity and estimated future cash flows. In addition to bond characteristics, the valuation methodologies incorporate market data, such as actual trades completed, bids and actual dealer quotes, where such information is available. Accordingly, the estimated fair values are based on available market information and judgments about financial instruments categorized within Level 1 and Level 2 of the fair value hierarchy. Interest and dividends are recorded when earned. Realized gains and losses on investments are determined by specific identification and are recognized as incurred in the condensed statement of operations. Changes in net unrealized gains and losses are reported in other comprehensive loss and represent the change in the fair value of investment holdings during the reporting period. Changes in net unrealized losses were $0.3 million and $0 for the three months ended March 31, 2023 and 2022, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	300000	usd
CY2022Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	usd
CY2023Q1	lgvn	Accounts And Grants Receivable AccountsAndGrantsReceivable	96000	usd
CY2022Q4	lgvn	Accounts And Grants Receivable AccountsAndGrantsReceivable	218000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	224000	usd
CY2023Q1	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	1190450000	usd
CY2023Q1	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	66862000	usd
CY2023Q1	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	9950490000	usd
CY2023Q1	us-gaap	Deferred Revenue DeferredRevenue	100000	usd
CY2022Q1	us-gaap	Deferred Revenue DeferredRevenue	0	usd
CY2022Q4	lgvn	Us Treasury Obligations USTreasuryObligations	96981000	usd
CY2023Q1	us-gaap	Revenues Revenues	279000	usd
CY2022Q1	us-gaap	Revenues Revenues	370000	usd
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Concentrations of credit risk: </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments which potentially subject the Company to credit risk consist principally of cash and cash equivalents, marketable securities and accounts and grants receivable. Cash and cash equivalents are held in U.S. financial institutions. At times, the Company may maintain balances in excess of the federally insured amounts.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q1	us-gaap	Discontinued Operation Provision For Loss Gain On Disposal Net Of Tax DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax	0	usd
CY2022Q1	us-gaap	Discontinued Operation Provision For Loss Gain On Disposal Net Of Tax DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax	0	usd
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P10Y
CY2023Q1	lgvn	Us Treasury Obligations USTreasuryObligations	98133000	usd
CY2023Q1	us-gaap	Us Government Agencies Securities At Carrying Value USGovernmentAgenciesSecuritiesAtCarryingValue	1064992000	usd
CY2023Q1	us-gaap	Life Insurance Corporate Or Bank Owned Amount LifeInsuranceCorporateOrBankOwnedAmount	7530053000	usd
CY2022Q4	us-gaap	Us Government Agencies Securities At Carrying Value USGovernmentAgenciesSecuritiesAtCarryingValue	1250003000	usd
CY2022Q4	us-gaap	Life Insurance Corporate Or Bank Owned Amount LifeInsuranceCorporateOrBankOwnedAmount	7807655000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	224000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	224000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	238000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6718000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6676000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Other Accumulated Depreciation PropertyPlantAndEquipmentOtherAccumulatedDepreciation	3908000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Other Accumulated Depreciation PropertyPlantAndEquipmentOtherAccumulatedDepreciation	3727000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2810000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2949000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	200000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	100000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3167000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-742000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2425000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3094000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-685000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2409000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1302000	usd
CY2022Q4	us-gaap	Other Expenses OtherExpenses	200000	usd
CY2022Q4	lgvn	Sharebased Compensation Arrangement Sharebased Payment Award Expiration Period SharebasedCompensationArrangementSharebasedPaymentAwardExpirationPeriod	P48M
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	10000	shares
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage	0.25	pure
CY2022Q3	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	4.67
CY2022Q3	lgvn	Calculation Price CalculationPrice	4.15
CY2023Q1	lgvn	Right Of Use Asset RightOfUseAsset	1500000	usd
CY2023Q1	lgvn	Lease Liabilitys LeaseLiabilitys	2500000	usd
CY2022Q4	lgvn	Right Of Use Asset RightOfUseAsset	1500000	usd
CY2022	lgvn	Lease Liabilitys LeaseLiabilitys	2600000	usd
CY2023Q1	lgvn	Lessee Operating Lease Liability Payments Due Next Twelve Month LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonth	518000	usd
CY2023Q1	lgvn	Lessee Operating Lease Liability Payments Due Year Two1 LesseeOperatingLeaseLiabilityPaymentsDueYearTwo1	702000	usd
CY2023Q1	lgvn	Lessee Operating Lease Liability Payments Due Year Three1 LesseeOperatingLeaseLiabilityPaymentsDueYearThree1	718000	usd
CY2023Q1	lgvn	Lessee Operating Lease Liability Payments Due Year Fours LesseeOperatingLeaseLiabilityPaymentsDueYearFours	735000	usd
CY2023Q1	lgvn	Lessee Operating Lease Liability Payments Due Year Fives LesseeOperatingLeaseLiabilityPaymentsDueYearFives	185000	usd
CY2023Q1	lgvn	Lessee Operating Lease Liability Payments Due After Year Five Net LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFiveNet	2858000	usd
CY2023Q1	lgvn	Operating Lease Interest Expense OperatingLeaseInterestExpense	392000	usd
CY2023Q1	us-gaap	Product Liability Contingency Accrual Present Value ProductLiabilityContingencyAccrualPresentValue	2466000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	300000	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	300000	usd
CY2020Q3	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P1Y
CY2020Q3	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	10000	usd
CY2023Q1	us-gaap	Sublease Income SubleaseIncome	0	usd
CY2022Q1	us-gaap	Sublease Income SubleaseIncome	30000	usd
CY2022	us-gaap	Sublease Income SubleaseIncome	27000	usd
CY2022	lgvn	Receiving Of Equipment ReceivingOfEquipment	17000	usd
CY2022Q4	us-gaap	Security Deposit SecurityDeposit	10000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	20161	shares
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	18005	shares
CY2023Q1	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	3.37
CY2023Q1	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option Unrealized Gain Loss Arising During Period Before Tax OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionUnrealizedGainLossArisingDuringPeriodBeforeTax	15000	usd
CY2023Q1	lgvn	Employee And Employer Taxes EmployeeAndEmployerTaxes	17000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	20157	shares
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	18001	shares
CY2022Q4	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	3.75
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost	100000	usd
CY2022Q3	lgvn	Sharebased Compensation Arrangement Sharebased Payment Award Expiration Period SharebasedCompensationArrangementSharebasedPaymentAwardExpirationPeriod	P48M
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	22000	shares
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage	0.25	pure
CY2022Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	5.94
CY2022Q1	lgvn	Calculation Price CalculationPrice	5.23
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost	100000	usd
CY2022Q4	lgvn	Directors Vested Description DirectorsVestedDescription	the Company recorded a tax liability of $16,000 for the employees and a corresponding tax liability for the Company of $2,000. In total, the Company paid $18,000 for employee and employer taxes that resulted from the vesting of RSUs. In order to cover the employee tax liability, the Company withheld 4,204 shares of Class A Common Stock owned by the Company’s employees upon vesting.
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	20158	shares
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	18002	shares
CY2022Q3	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	5.94
CY2022Q3	lgvn	Directors Vested Description DirectorsVestedDescription	the Company recorded a tax liability of $26,000 for the employees and a corresponding tax liability for the Company of $2,000. In total, the Company paid $28,000 for employee and employer taxes that resulted from the vesting of RSUs. In order to cover the employee tax liability, the Company withheld 4,726 shares of Class A Common Stock owned by the Company’s employees upon vesting.
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	27854	shares
CY2022Q2	us-gaap	Deferred Compensation Arrangement With Individual Compensation Expense DeferredCompensationArrangementWithIndividualCompensationExpense	170000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	26666	shares
CY2022Q2	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	8.73
CY2022Q2	lgvn	Employee And Employer Taxes EmployeeAndEmployerTaxes	55000	usd
CY2022Q2	lgvn	Cash Payment CashPayment	57000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	1167	shares
CY2022Q2	lgvn	Directors Vested Description DirectorsVestedDescription	Based on the closing price of $12.85 on April 3, 2022, the Company recorded a tax liability of $5,000 for the employee and a corresponding tax liability for the Company of $1,000. In total, the Company paid $6,000 for employee and employer taxes that resulted from the vesting of RSUs. In order to cover the employee tax liability, the Company withheld 357 shares of Class A Common Stock owned by the Chief Medical Officer upon vesting.
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	31016	shares
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	26360	shares
CY2022Q2	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	15.61
CY2022Q2	lgvn	Directors Vested Description DirectorsVestedDescription	the Company recorded a tax liability of $105,000 for the employees and a corresponding tax liability for the Company of $14,000. In total, the Company paid $119,000 for employee and employer taxes that resulted from the vesting of RSUs. In order to cover the employee tax liability, the Company withheld 6,222 shares of Class A Common Stock owned by the Company’s employees upon vesting.
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	8750	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	35246	shares
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	29614	shares
CY2022Q1	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	12.09
CY2022Q1	lgvn	Directors Vested Description DirectorsVestedDescription	the Company recorded a tax liability of $92,000 for the employees and a corresponding tax liability for the Company of $14,000. In total, the Company paid $106,000 for employee and employer taxes that resulted from the vesting of RSUs. In order to cover the employee tax liability, the Company withheld 10,627 shares of Class A Common Stock owned by the Company’s employees upon vesting.
CY2021Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	500000	usd
CY2021	lgvn	Underwriters Warrants UnderwritersWarrants	95760	shares
CY2023Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	17.5
CY2023Q1	lgvn	Warrants Expire Term WarrantsExpireTerm	P5Y
CY2023Q1	lgvn	Sharebased Compensation Timebased Vesting Stock Option SharebasedCompensationTimebasedVestingStockOption	50000	shares
CY2023Q1	lgvn	Sharebased Compensation Performance Share Units SharebasedCompensationPerformanceShareUnits	125000	shares
CY2022Q4	lgvn	Aggregate Value AggregateValue	207000	usd
CY2022Q3	lgvn	Vest First Year Anniversary Percentage VestFirstYearAnniversaryPercentage	0.25	pure
CY2022Q3	lgvn	Vest Third Year Anniversary Percentage VestThirdYearAnniversaryPercentage	0.25	pure
CY2022Q3	lgvn	Vest Second Year Anniversary Percentage VestSecondYearAnniversaryPercentage	0.25	pure
CY2022Q3	lgvn	Vest Fourth Year Anniversary Percentage VestFourthYearAnniversaryPercentage	0.25	pure
CY2022Q1	lgvn	Sharebased Compensation Arrangement Sharebased Payment Award Expiration Period SharebasedCompensationArrangementSharebasedPaymentAwardExpirationPeriod	P48M
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	84825	shares
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage	0.25	pure
CY2022Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	10
CY2022Q1	lgvn	Calculation Price CalculationPrice	8.78
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost	700000	usd
CY2022Q1	lgvn	Sharebased Compensation Arrangement Sharebased Payment Award Expiration Period SharebasedCompensationArrangementSharebasedPaymentAwardExpirationPeriod	P48M
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	400000	usd
CY2022Q2	lgvn	Employment Agreement Description EmploymentAgreementDescription	the Company appointed K. Chris Min, M.D., Ph.D. as its Chief Medical Officer. Dr. Min’s employment agreement provides annual base salary of $350,000, and he will be eligible to receive a performance bonus equal to 30% of his base salary, prorated for his first year of employment. Dr. Min received a $60,000 signing bonus, with 50% of this amount paid in RSUs and 50% in stock options. Dr. Min also received two equity incentive awards: 150,000 RSUs and a stock option award exercisable for 50,000 shares. Each award will vest 25% upon the first-year anniversary of his first day of employment with Longeveron, with 25% vesting thereafter on the second, third and fourth anniversaries of his employment. In each case, the vesting of the equity awards will be subject to Dr. Min’s continued service through the applicable vesting dates. RSUs shall be expensed on a quarterly basis at the rate of $0.1 million for the quarterly vesting amount of 9,375 RSUs, with a price per share of $12.85 (the closing price of the Company’s stock on April 4, 2022). Stock options shall be expensed based upon a Black-Scholes calculation, the price per share to be expensed was $11.34 and a total cost of $0.6 million would be expensed ratably over 48 months.
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	356297	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	329746	shares
CY2022Q4	lgvn	Sharebased Compensation Arrangement By Sharebased Payment Award Options Right Of Use Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsRightOfUseOutstanding	329746	shares
CY2023Q1	lgvn	Share Based Compensation Arrangement By Share Based Payment Award Options Right Of Use Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRightOfUseGranted	50000	shares
CY2023Q1	lgvn	Sharebased Compensation Arrangement By Share Based Payment Award Options Rs Us Vested SharebasedCompensationArrangementByShareBasedPaymentAwardOptionsRSUsVested	-23149	shares
CY2023Q1	lgvn	Sharebased Compensation Arrangement By Sharebased Payment Award Options Right Of Use Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsRightOfUseOutstanding	356597	shares
CY2023Q1	lgvn	Grant Shares GrantShares	0.05	pure
CY2023Q1	lgvn	Dividend Yield dividendYield	0	pure
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.95	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	470191	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	470191	shares
CY2022Q4	lgvn	Directors Total DirectorsTotal	45000	usd
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage	0.25	pure
CY2022Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	3
CY2022Q4	lgvn	Calculation Price CalculationPrice	2.67
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost	135000	usd
CY2022Q4	lgvn	Sharebased Compensation Arrangement Sharebased Payment Award Expiration Period SharebasedCompensationArrangementSharebasedPaymentAwardExpirationPeriod	P48M
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	22843	shares
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage	0.25	pure
CY2022Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	4.3
CY2022Q4	lgvn	Calculation Price CalculationPrice	2.94
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost	100000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	500000	usd
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	3200000	usd
CY2023Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P3Y10M24D
CY2023Q1	lgvn	Agreements Amount AgreementsAmount	3500000	usd
CY2023Q1	lgvn	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm	P2Y
CY2022Q4	lgvn	Isuuance Of Addritional Unrigistered Shares IsuuanceOfAddritionalUnrigisteredShares	48140	shares
CY2017Q4	lgvn	Aggregate Of Accrued Technology Service AggregateOfAccruedTechnologyService	200000	usd
CY2023Q1	lgvn	Owed Amount OwedAmount	100000	usd
CY2022	lgvn	Owed Amount OwedAmount	100000	usd
CY2023Q1	lgvn	License Issue Fees licenseIssueFees	5000	usd
CY2023Q1	lgvn	Agreement Term AgreementTerm	P20Y
CY2023Q1	us-gaap	Acquisition Costs AcquisitionCosts	100000	usd
CY2023Q1	lgvn	Defray Patent Costs DefrayPatentCosts	500000	usd
CY2023Q1	us-gaap	Accounts Payable Other Current And Noncurrent AccountsPayableOtherCurrentAndNoncurrent	140000	usd
CY2022Q4	us-gaap	Accounts Payable Other Current And Noncurrent AccountsPayableOtherCurrentAndNoncurrent	140000	usd
CY2023Q1	lgvn	Accrued Amount AccruedAmount	92000	usd
CY2022Q4	lgvn	Accrued Amount AccruedAmount	50000	usd
CY2023Q1	lgvn	Reimbursements Based Amount ReimbursementsBasedAmount	100000	usd
CY2023Q1	lgvn	Agreement Description AgreementDescription	The Company is required to pay as royalty, 1% of the annual net sales of the licensed product(s) used, leased, or sold by or for licensee or its sub-licensees. If the Company sublicenses the technology, it is also required to pay an amount equal to 10% of the net sales of the sub-licensees. In addition, on December 23, 2016, as required by the license agreement, the Company paid an initial fee of $250,000 to JMHMD, and issued to it 10,000 Series C Units, valued at $250,000. The $0.5 million of value provided to JMHMD for the license agreement, along with professional fees of approximately $27,000, were recorded as an intangible asset that is amortized over the life of the license agreement which was defined as 20 years. Further, expenses related to the furtherance of the CD271+ technology is being capitalized and amortized as incurred over 20 years. There were no license fees due for March 31, 2023 and December 31, 2022 pertaining to this agreement.
CY2023Q1	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	38000	usd
CY2022Q1	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	32000	usd
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2097	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1881	shares
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	Longeveron Inc.
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.22
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20911203	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21033610	shares
CY2022Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Before Reclassification Adjustments Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax		usd
CY2023Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures		usd
CY2022Q1	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits		usd
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures		usd
CY2023Q1	lgvn	Share Based Compensation Arrangement By Share Based Payment Award Options Right Of Use Expiredforfeited ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRightOfUseExpiredforfeited		shares
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001721484

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
lgvn-20230331_def.xml	Edgar Link	unprocessable
lgvn-20230331_cal.xml	Edgar Link	unprocessable
0001213900-23-039003-index-headers.html	Edgar Link	pending
0001213900-23-039003-index.html	Edgar Link	pending
0001213900-23-039003.txt	Edgar Link	pending
0001213900-23-039003-xbrl.zip	Edgar Link	pending
f10q0323ex31-1_longeveroninc.htm	Edgar Link	pending
f10q0323ex31-2_longeveroninc.htm	Edgar Link	pending
f10q0323ex32-1_longeveroninc.htm	Edgar Link	pending
f10q0323_longeveroninc.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
lgvn-20230331.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
lgvn-20230331_pre.xml	Edgar Link	unprocessable
lgvn-20230331_lab.xml	Edgar Link	unprocessable
f10q0323_longeveroninc_htm.xml	Edgar Link	completed
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LGVN
Longeveron Inc. Stock $lgvn

2023 Q1 Form 10-Q Financial Statement

#000121390023039003 Filed on May 12, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LGVN Longeveron Inc. Stock $lgvn

2023 Q1 Form 10-Q Financial Statement

#000121390023039003 Filed on May 12, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LGVN
Longeveron Inc. Stock $lgvn